Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

5.73
-0.1000-1.72%
Volume:92.69K
Turnover:527.17K
Market Cap:335.67M
PE:-5.00
High:5.77
Open:5.77
Low:5.22
Close:5.83
52wk High:6.95
52wk Low:2.94
Shares:58.58M
Float Shares:28.87M
Volume Ratio:0.76
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1460
EPS(LYR):-1.5778
ROE:-470.38%
ROA:-21.07%
PB:-3.74
PE(LYR):-3.63

Loading ...

Guggenheim Initiates Coverage on Foghorn Therapeutics With Buy Rating, $12 Price Target

MT Newswires Live
·
Nov 07, 2025

Foghorn Therapeutics: Promising Pipeline and Strategic Collaborations Drive Buy Rating

TIPRANKS
·
Nov 06, 2025

BRIEF-Foghorn Therapeutics Inc - On Oct 31, Kristian Humer Resigned As CFO Effective November 14, 2025 - SEC Filing

Reuters
·
Nov 05, 2025

Foghorn Therapeutics Q3 collaboration revenue rises, net loss narrows on Lilly partnership

Reuters
·
Nov 05, 2025

Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate

Benzinga
·
Nov 05, 2025

BRIEF-Foghorn Therapeutics Q3 EPS USD -0.25

Reuters
·
Nov 05, 2025

Foghorn Therapeutics Q3 Net Income USD -15.849 Million

THOMSON REUTERS
·
Nov 05, 2025

Foghorn Therapeutics Q3 Collaboration Revenue USD 8.153 Million

THOMSON REUTERS
·
Nov 05, 2025

Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

GlobeNewswire
·
Nov 05, 2025

Foghorn Therapeutics: Promising Advancements in ARID1B-Degrader Program and Strategic Focus Justify Buy Rating

TIPRANKS
·
Nov 04, 2025

Foghorn Therapeutics to Participate in Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 03, 2025

Foghorn Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
Oct 31, 2025

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Bicycle Therapeutics (BCYC) and Foghorn Therapeutics (FHTX)

TIPRANKS
·
Oct 31, 2025

Foghorn Therapeutics Inc - Selective Cbp Degrader Ind-Ready in 2026

THOMSON REUTERS
·
Oct 30, 2025

Foghorn Therapeutics Inc - Selective Arid1b Degrader Relevant in 5% of Solid Tumors

THOMSON REUTERS
·
Oct 30, 2025

Foghorn Therapeutics Announces Updates for Selective Arid1b, Selective Cbp and Selective Ep300 Degrader Programs

THOMSON REUTERS
·
Oct 30, 2025

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

GlobeNewswire
·
Oct 30, 2025

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader Program Targeting Cancer at TPD Summit

Reuters
·
Oct 16, 2025

Foghorn Therapeutics Announces Significant Progress for Selective Arid1b Degrader at the 8TH Annual Tpd and Induced Proximity Summit

THOMSON REUTERS
·
Oct 16, 2025

Foghorn Therapeutics transferred with Buy rating at B. Riley

TIPRANKS
·
Sep 17, 2025